TBI
TrueBlue, Inc.
TBI's outlook is improving, though it still trails on the overall score.
VRT
Vertiv Holdings Co
VRT has the edge over TBI overall, supported by stronger valuation and stronger fundamentals.
TBI Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Weak |
TBI's revenue is currently healthy, but its profitability, cash flow and balance sheet are under pressure.
VRT Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
VRT's revenue, profitability, cash flow and balance sheet are all currently strong.
TBI PE Valuation
TBI has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 18x next year's earnings.
VRT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 23x | $210 | — |
| Current | 39x | $210 | — |
| Cheap | 58x | $308 | +47% |
| Fair | 72x | $383 | +83% |
| Expensive | 88x | $472 | +125% |
Historical ranges are pointers, not guarantees.
VRT's PE is in its cheap range at 39x. If earnings grow as analysts expect, today's price would be 23x next year's earnings.
TBI Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect TBI to return to profit, with revenue growing.
VRT Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Moderate | |
| Moderate |
Analysts expect strong earnings and revenue growth for VRT, with profitability improving.
TBI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.69 | — |
| Q3 2026 | -$1.55 | -$0.59 |
| Q2 2026 | -$1.89 | -$0.73 |
| Q1 2026 | -$1.79 | +$2.81 |
| Q4 2025 | -$1.61 | +$2.56 |
| Q3 2025 | -$0.96 | +$2.88 |
| Q2 2025 | -$1.16 | +$2.42 |
| Q1 2025 | -$4.60 | -$4.23 |
| Q4 2024 | -$4.17 | -$3.72 |
TBI is still losing money, but far less than before: $1.55 per share over the past year, against $4.60 at its worst in early 2025.
VRT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.14 | +71% |
| Q3 2026 | $5.35 | +102% |
| Q2 2026 | $4.42 | +111% |
| Q1 2026 | $3.98 | +131% |
| Q4 2025 | $3.41 | +166% |
| Q3 2025 | $2.65 | +75% |
| Q2 2025 | $2.09 | +62% |
| Q1 2025 | $1.72 | +64% |
| Q4 2024 | $1.28 | +7.6% |
VRT has the edge over TBI on earnings quality, reporting a profit while its opponent remains loss making.
TBI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $520.7M | +21% |
| Q2 2026 | $443M | +12% |
| Q1 2026 | $398.6M | +7.6% |
| Q4 2025 | $418.2M | +8.3% |
| Q3 2025 | $431.3M | +13% |
| Q2 2025 | $396.3M | 0% |
| Q1 2025 | $370.3M | -8.1% |
| Q4 2024 | $386M | -22% |
TBI's revenue is recovering but still below its 2021 peak: $521M last quarter, up 21% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 2.3% | +2.3 points |
| Q2 2026 | -0.3% | +0.5 points |
| Q1 2026 | -4.5% | -0.7 points |
| Q4 2025 | -7% | -4.3 points |
| Q3 2025 | 0% | +1.8 points |
| Q2 2025 | -0.7% | +14 points |
| Q1 2025 | -3.8% | 0 points |
| Q4 2024 | -2.7% | -1 points |
TBI's operating margin was 2.3% last quarter, up 2.3 points from the same quarter a year ago.
VRT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $4.3B | +61% |
| Q2 2026 | $3.3B | +24% |
| Q1 2026 | $2.6B | +30% |
| Q4 2025 | $2.9B | +23% |
| Q3 2025 | $2.7B | +29% |
| Q2 2025 | $2.6B | +35% |
| Q1 2025 | $2B | +24% |
| Q4 2024 | $2.3B | +26% |
VRT has the edge over TBI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 23% | +3.5 points |
| Q2 2026 | 19% | +2.7 points |
| Q1 2026 | 17% | +2.3 points |
| Q4 2025 | 20% | +0.7 points |
| Q3 2025 | 19% | +1.4 points |
| Q2 2025 | 17% | -0.4 points |
| Q1 2025 | 14% | +1.9 points |
| Q4 2024 | 19% | +4.2 points |
VRT has the edge over TBI on profitability, with a higher operating margin.
TBI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$28.3M | -$4.9M |
| Q2 2026 | -$24M | -$7.9M |
| Q1 2026 | -$12.6M | +$14.2M |
| Q4 2025 | -$7.5M | -978% |
| Q3 2025 | -$23.4M | -$10.7M |
| Q2 2025 | -$16.1M | -$8.3M |
| Q1 2025 | -$26.8M | -$5.2M |
| Q4 2024 | $854K | -88% |
TBI has burned cash in seven of the last eight quarters: −$72M over the past year, against −$65M the year before.
VRT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $654.9M | +41% |
| Q2 2026 | $926.5M | +233% |
| Q1 2026 | $654.2M | +145% |
| Q4 2025 | $885.6M | +143% |
| Q3 2025 | $463.5M | +36% |
| Q2 2025 | $277.9M | -19% |
| Q1 2025 | $266.8M | +162% |
| Q4 2024 | $364.5M | +18% |
VRT has the edge over TBI on cash generation, producing positive trailing cash flow while its opponent burns cash.
TBI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +7.3% | +2.2M shares |
| 1 year | +9.2% | +2.7M shares |
| 3 years | +5.5% | +1.7M shares |
| 5 years | -8% | -2.8M shares |
| Available history | -17% | -6.5M shares |
TBI has 33M diluted shares, up 9.2% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $8,000 |
| Q3 2024 | $4.3M |
| Q2 2024 | $6.9M |
| Q1 2024 | $10.1M |
VRT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -64.9K shares |
| 1 year | +0.4% | +1.8M shares |
| 3 years | +1.1% | +4.4M shares |
| 5 years | +10% | +36M shares |
| Available history | +63% | +152M shares |
VRT has the edge over TBI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | $599.9M |
TBI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | 929.0x | High |
| Q4 2023 | -31.4x | Net Cash |
| Q3 2023 | -2.7x | Net Cash |
| Q2 2023 | -1.1x | Net Cash |
| Q1 2023 | -0.6x | Net Cash |
| Q4 2022 | -0.7x | Net Cash |
| Q3 2022 | -0.4x | Net Cash |
| Q2 2022 | -0.3x | Net Cash |
TBI's net debt is more than 20 years of its operating earnings (EBITDA), after holding more cash than debt a year ago.
VRT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.2x | Net Cash |
| Q2 2026 | 0.1x | Very low |
| Q1 2026 | 0.3x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.8x | Very low |
| Q2 2025 | 0.7x | Very low |
| Q1 2025 | 0.8x | Very low |
| Q4 2024 | 1.0x | Healthy |
VRT has more cash than debt.
TBI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 70.8 | Overbought |
| Stochastic | 74.6 | Neutral |
TBI's weekly RSI is 71 (overbought) and its Stochastic is 75 (neutral).
VRT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 26.4 | Neutral |
VRT's weekly RSI is 43 (neutral) and its Stochastic is 26 (neutral).
TBI PE vs Industrials Sector
| Metric | TBI | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 24x | — |
TBI has no meaningful PE right now: it lost money over the past year.
VRT PE vs Industrials Sector
| Metric | VRT | Sector median | Relative |
|---|---|---|---|
| PE | 39x | 24x | 63% above |
| PE % | 3 | 58 | 55 pts below |
VRT is trading at 39x earnings, a 63% premium to the Industrials sector's median of 24x.
TBI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.92 | 24% above |
| 20 week MA | $9.34 | 32% above |
| 50 week MA | $6.73 | 84% above |
| 100 week MA | $6.42 | 92% above |
| 200 week MA | $9.78 | 26% above |
TBI has the edge over VRT on trend strength, trading above more of its moving averages.
VRT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $221.8 | 5.5% below |
| 20 week MA | $254.4 | 18% below |
| 50 week MA | $253.9 | 17% below |
| 100 week MA | $189.1 | 11% above |
| 200 week MA | $123.5 | 70% above |
VRT has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 70% above its 200-week average.
TBI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $23.6 | $19.2 | -19% |
| 2021 | $19.2 | $27.7 | +44% |
| 2022 | $27.7 | $19.2 | -30% |
| 2023 | $19.2 | $15.3 | -20% |
| 2024 | $15.3 | $7.87 | -49% |
| 2025 | $7.87 | $4.65 | -41% |
| 2026 YTD | $4.65 | $12.4 | +166% |
TBI has the edge over VRT on returns for 2026, with the stronger performance.
VRT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $10.9 | $18.9 | +73% |
| 2021 | $18.9 | $24.9 | +31% |
| 2022 | $24.9 | $12.8 | -48% |
| 2023 | $12.8 | $48.0 | +275% |
| 2024 | $48.0 | $115.1 | +140% |
| 2025 | $115.1 | $167.6 | +46% |
| 2026 YTD | $167.6 | $209.6 | +25% |
VRT's yearly returns have swung widely, from +275% in 2023 to −48% in 2022. It's up 25% so far in 2026.